Г ема т о л о г и я УДК 615.361.4-013.3].012.036.8 Granulocyte colony-stimulating factor: the development and clinical use (Review of literature) K.Welte Hannover Medical School, Hannover, Germany The identification, purification and molecular cloning of granulocyte colony-stimulating factor (G-CSF) in the 1980s; the nonclinical studies; and the subsequent development of G-CSF as a therapeutic agent in the late 1980s and 1990s have had a major influence on the treatment of many diseases. <...> In the clinical setting, filgrastim and lenograstim are of benefit to patients receiving chemotherapy or myeloablative treatment. <...> Stem cell transplantation using G-CSF-mobilised peripheral blood stem cells revolutionised stem cell transplantation, making it simpler, more efficient and more widely applicable in the clinic. <...> This review discusses the development and clinical uses of G-CSF – filgrastim and lenograstim. <...> Key words: granulocyte colony-stimulating factor, development, clinical use, filgrastim, lenograstim Biochemical characteristics of granulocyte colony-stimulating factor D.Metcalf [1] pointed out the value of more than 50 years of research before the initiation of the clinical development of granulocyte colony-stimulating factor (G-CSF). <...> Deduced from the aminoacid sequence, molecular cloning of the cDNA for G-CSF and the first expression in Escherichia coli were achieved in 1986 by L.Souza et al. [3]. <...> The recombinant G-CSF (filgrastim) was capable of supporting proliferation and differentiation in myeloid progenitor cell – PC (colony-forming units-granulocyte/macrophage – CFU-GM) assays. <...> We were also able to identify G-CSF receptors (G-CSFR) on myeloid leukaemia cells by binding studies with 125 I-labelled G-CSF [3]. <...> In the same 1986 a Japanese group purified G-CSF from the cell line CHU-2 [4], and S.Nagata et al. [5] cloned the cDNA encoding G-CSF from the same cell line by using probes derived from the partial amino-acid sequence of the purified G-CSF from CHU-2 cells. <...> In a Corresponding author: Welte Karl, MD, PhD, Prof., Head of the Department of Molecular Hematopoiesis, Hannover Medical School Address: Carl-Neuberg Street, 1, 30625, Hannover, Germany Phone: +49-511-532-9037 E-mail: Welte.Karl.H@mh-hannover.de Received 01.12.2014, accepted for publication 16.12.2014. 6 Fig. 2. <...> Purification of G-CSF in Memorial Sloan-Kettering <...>